Since its introduction 6 years ago, imatinib mesylate, a selective tyrosine kinase inhibitor, has been a phenomenon in treating chronic myelogenous leukemia (CML) with remarkably superior cytogenetic and molecular response rates at all stages of CML followed by longer progression free survival.
--
Posted by Rob to
CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 2/17/2006 11:16:30 PM
--~--~---------~--~----~------------~-------~--~----~
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to CMLHope@googlegroups.com
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
